Surya is currently a Business Development Analyst at Precigen, a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. His role is to facilitate strategic partnerships with key stakeholders; assist in drafting proposals, contracts, and marketing content; track key industry trends; portfolio management; and competitive intelligence. Essentially, he provides industry context to the R&D activities that are ongoing at Precigen to help leadership make strategic decisions with potential partners.
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced fourth quarter and full year 2021 financial results.
At the American Society of Hematology meeting earlier this month, Precigen presented positive interim data from an ongoing Phase 1/2b clinical study of PRGN-3006 UltraCAR-T in patients who have been diagnosed with relapsed or refractory (r/r) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS). The interim study data showed what the trial investigators are calling “excellent, dose-dependent expansion.”
Investors Eye Gene Therapy Companies and Rapidly Expanding Market – Five Publicly Traded Gene Therapy Companies
Forbes recently honored two Maryland biotech CEOs, naming them to the 50 Over 50 list of female visionaries. The local awardees are Helen Sabzevari of Precigen and Carol Nacy of Sequella. Sabzevari focuses on cancer treatment, and Nacy battles tuberculosis.
50 Over 50: How This Iranian Immigrant’s Vision Could Revolutionize Cancer Treatment
Germantown’s Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)
Germantown’s Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP) GERMANTOWN, Md., March 23, 2021 /PRNewswire/ — Precigen, Inc., a biopharmaceutical company specializing in the development [….]